Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-08-05

Last Posted Date: 2009-02-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004080

Flavopiridol in Treating Patients With Recurrent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: alvocidib

First Posted Date: 2004-08-02

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003256

Locations: 🇺🇸
Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

Phase 2

Completed

Conditions: Hippel-Lindau Disease
Kidney Cancer

Interventions: Drug: 17 allylamino-17-demethoxygeldanamycin
Drug: 18 FDG (Fludeoxyglucose 18F)
Drug: [15-O] H2O
Drug: EPL diluent

First Posted Date: 2004-07-26

Last Posted Date: 2012-07-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT00088374

Locations: 🇺🇸
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

Effect of Tenofovir DF on Bone Metabolism in Children

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2004-07-26

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00088309

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

Phase 1

Completed

Conditions: Breast Cancer
Colorectal Cancer
Ovarian Cancer
Adenocarcinoma

Interventions: Biological: PANVAC-V
Biological: PANVAC-F
Drug: Sargramostim (GM-CSF, Leukine)

First Posted Date: 2004-07-26

Last Posted Date: 2019-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00088413

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides

Phase 2

Conditions: Lymphoma

First Posted Date: 2004-07-19

Last Posted Date: 2013-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00002557

Locations: 🇿🇦
University of Cape Town School of Medicine, Cape Town, South Africa

Perillyl Alcohol in Treating Patients With Refractory Cancer

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: perillyl alcohol

First Posted Date: 2004-07-19

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00002862

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: ara-C
Drug: Daunorubicin
Drug: Etoposide
Biological: Aldesleukin
Drug: PSC-833

First Posted Date: 2004-07-19

Last Posted Date: 2012-11-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 410

Registration Number: NCT00002925

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States

and more 30 locations

Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer

Phase 3

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: fluorouracil
Drug: eniluracil

First Posted Date: 2004-07-16

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 950

Registration Number: NCT00003873

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-07-16

Last Posted Date: 2012-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00003853

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇮🇹
University of Pavia, Pavia, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy